Everett E. Vokes
About
Everett E. Vokes is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology.
According to data from OpenAlex, Everett E. Vokes has authored 774 papers receiving a total of 36.3k indexed citations (citations by other indexed papers that have themselves been cited), including 464 papers in Oncology, 428 papers in Pulmonary and Respiratory Medicine and 251 papers in Otorhinolaryngology. Recurrent topics in Everett E. Vokes's work include Lung Cancer Treatments and Mutations (290 papers), Head and Neck Cancer Studies (248 papers) and Lung Cancer Research Studies (172 papers). Everett E. Vokes is often cited by papers focused on Lung Cancer Treatments and Mutations (290 papers), Head and Neck Cancer Studies (248 papers) and Lung Cancer Research Studies (172 papers). Everett E. Vokes collaborates with scholars based in United States, France and Canada. Everett E. Vokes's co-authors include Ralph R. Weichselbaum, Daniel J. Haraf, Waun Ki Hong, Ezra E.W. Cohen, Scott M. Lippman, Joseph K. Salama, Kerstin Stenson, Tanguy Y. Seiwert, Ann M. Mauer and Walter M. Stadler and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.
In The Last Decade
Everett E. Vokes
749 papers receiving 35.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Everett E. Vokes United States | 95 | 19.2k | 15.5k | 9.8k | 9.6k | 7.6k | 774 | 36.3k | ||
| Jean‐Pierre Pignon France | 77 | 14.8k 0.8× | 16.3k 1.1× | 7.4k 0.8× | 4.0k 0.4× | 8.9k 1.2× | 305 | 31.0k | ||
| Arlene A. Forastiere United States | 68 | 10.8k 0.6× | 11.2k 0.7× | 16.0k 1.6× | 5.4k 0.6× | 13.6k 1.8× | 269 | 28.8k | ||
| Anthony T.�C. Chan Hong Kong | 86 | 11.7k 0.6× | 5.6k 0.4× | 10.2k 1.0× | 7.8k 0.8× | 7.2k 1.0× | 456 | 27.6k | ||
| Eric K. Rowinsky United States | 81 | 18.5k 1.0× | 9.6k 0.6× | 3.0k 0.3× | 12.1k 1.3× | 3.8k 0.5× | 396 | 32.1k | ||
| Waun Ki Hong United States | 98 | 12.7k 0.7× | 8.1k 0.5× | 5.3k 0.5× | 16.8k 1.8× | 4.3k 0.6× | 512 | 34.0k | ||
| Scott M. Lippman United States | 89 | 12.8k 0.7× | 10.6k 0.7× | 4.0k 0.4× | 13.5k 1.4× | 4.8k 0.6× | 528 | 37.2k | ||
| Quynh‐Thu Le United States | 79 | 7.8k 0.4× | 7.0k 0.4× | 7.4k 0.8× | 6.7k 0.7× | 5.8k 0.8× | 461 | 25.4k | ||
| Lillian L. Siu Canada | 81 | 11.6k 0.6× | 6.5k 0.4× | 3.4k 0.3× | 8.2k 0.9× | 4.1k 0.5× | 579 | 24.6k | ||
| Carsten Bokemeyer Germany | 89 | 14.2k 0.7× | 9.8k 0.6× | 1.7k 0.2× | 9.5k 1.0× | 11.6k 1.5× | 957 | 36.1k | ||
| Corey J. Langer United States | 73 | 17.1k 0.9× | 16.9k 1.1× | 2.3k 0.2× | 5.7k 0.6× | 3.1k 0.4× | 563 | 28.2k |
Countries citing papers authored by Everett E. Vokes
Since
Specialization
Citations
This map shows the geographic impact of Everett E. Vokes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Everett E. Vokes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Everett E. Vokes more than expected).
Fields of papers citing papers by Everett E. Vokes
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Everett E. Vokes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Everett E. Vokes. The network helps show where Everett E. Vokes may publish in the future.
Co-authorship network of co-authors of Everett E. Vokes
This figure shows the co-authorship network connecting the top 25 collaborators of Everett E. Vokes. A scholar is included among the top collaborators of Everett E. Vokes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Everett E. Vokes. Everett E. Vokes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Rosenberg, Ari J., Evgeny Izumchenko, Aditya Juloori, et al.. (2025). Early Dynamics of Circulating Tumor HPV-DNA with Neoadjuvant Chemotherapy and Response-Adapted De-escalation in Human Papillomavirus–Associated Oropharyngeal Cancer. Clinical Cancer Research. 31(15). 3150–3159.
2.
Pearson, Alexander T., Kedar Kirtane, Emily L. Bellile, et al.. (2024). Phase I/II Study of A Novel MDM-2 Inhibitor (APG-115-Alrizomadlin) in p53 Wild Type Salivary Gland Cancers. International Journal of Radiation Oncology*Biology*Physics. 118(5). e6–e7.
3.
Rosenberg, Ari J., Aditya Juloori, Evgeny Izumchenko, et al.. (2024). Neoadjuvant HPV16-specific arenavirus-based immunotherapy HB-200 plus chemotherapy followed by response-stratified de-intensification in HPV16+ oropharyngeal cancer: TARGET-HPV.. Journal of Clinical Oncology. 42(16_suppl). 6017–6017.
4.
Spicer, Jonathan, Nicolas Girard, Mariano Provencio, et al.. (2024). Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816.. Journal of Clinical Oncology. 42(17_suppl). LBA8010–LBA8010.
5.
Rosenberg, Ari J., Evgeny Izumchenko, Aditya Juloori, et al.. (2023). 886P Prospective evaluation of dynamic changes of cell-free HPV-DNA (cfHPV-DNA) in locoregional HPV associated (HPV+) oropharyngeal cancer (OPC) treated with neoadjuvant chemotherapy and response-stratified treatment. Annals of Oncology. 34. S568–S568.
6.
Rosenberg, Ari J., Theodore Karrison, Jonas A. de Souza, et al.. (2023). A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Annals of Oncology. 34(8). 714–722.
7.
Camidge, D. Ross, Daniel Morgensztern, Rebecca S. Heist, et al.. (2021). Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma. Clinical Cancer Research. 27(21). 5781–5792.
8.
Rao, Enyu, Yuzhu Hou, Xiaona Huang, et al.. (2021). All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages. Science Immunology. 6(60).
9.
Ferris, Robert L., Lisa Licitra, Jérôme Fayette, et al.. (2019). Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clinical Cancer Research. 25(17). 5221–5230.
10.
Saloura, Vassiliki, Makda Zewde, Kazuma Kiyotani, et al.. (2017). Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research. 23(16). 4897–4907.
11.
Koshy, Matthew, Philip P. Connell, Everett E. Vokes, et al.. (2017). Impact of Cardiac Dose on Cardiac Events and Survival in Unresectable Lung Cancer Patients. International Journal of Radiation Oncology*Biology*Physics. 98(1). 247–247.
12.
Sasaki, Mark M., Andrew D. Skol, Riyue Bao, et al.. (2015). Integrated Genomic Analysis Suggests MLL3 Is a Novel Candidate Susceptibility Gene for Familial Nasopharyngeal Carcinoma. Cancer Epidemiology Biomarkers & Prevention. 24(8). 1222–1228.
13.
Kawada, Ichiro, Rifat Hasina, Jeffrey Mueller, et al.. (2013). Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non–Small Cell Lung Cancer. Cancer Research. 74(3). 884–895.
14.
Cohen, Ezra E.W., Daniel J. Haraf, Rangesh Kunnavakkam, et al.. (2010). Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck Cancer. Journal of Clinical Oncology. 28(20). 3336–3343.
15.
Kuo, Wen‐Liang, Jing Liu, Helena J. Mauceri, et al.. (2010). Efficacy of the Multi-Kinase Inhibitor Enzastaurin Is Dependent on Cellular Signaling Context. Molecular Cancer Therapeutics. 9(10). 2814–2824.
16.
Seiwert, Tanguy Y., Ramasamy Jagadeeswaran, Leonardo Faoro, et al.. (2009). The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma. Cancer Research. 69(7). 3021–3031.
17.
Cohen, Ezra E.W., Lee S. Rosen, Everett E. Vokes, et al.. (2008). Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study. Journal of Clinical Oncology. 26(29). 4708–4713.
18.
Strauss, Gary M., James E. Herndon, Michael A. Maddaus, et al.. (2008). Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. Journal of Clinical Oncology. 26(31). 5043–5051.
19.
Fleming, Gini F., Linda Janisch, Nicholas J. Vogelzang, Everett E. Vokes, & Mark J. Ratain. (1996). Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support. Cancer. 77(11). 2308–2312.
20.
Vokes, Everett E., H M Golomb, Brian L. Samuels, & Bernard H. Brownstein. (1989). Heat Shock Proteins in Normal and Leukemic Blood Cells. Journal of Interferon Research. 9(2). 195–204.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jean‐Pierre Pignon Breakdown of academic impact, for papers by Arlene A. Forastiere Breakdown of academic impact, for papers by Anthony T.�C. Chan Breakdown of academic impact, for papers by Eric K. Rowinsky Breakdown of academic impact, for papers by Waun Ki Hong Breakdown of academic impact, for papers by Scott M. Lippman Breakdown of academic impact, for papers by Quynh‐Thu Le Breakdown of academic impact, for papers by Lillian L. Siu Breakdown of academic impact, for papers by Carsten Bokemeyer Breakdown of academic impact, for papers by Corey J. Langer